| Literature DB >> 29478281 |
Satoyo Hosono1,2, Teruhiko Terasawa3, Takafumi Katayama4, Seiju Sasaki5, Keika Hoshi6, Chisato Hamashima7.
Abstract
The Bethesda system (TBS) has been used for cervical cytological diagnosis in Japan since 2008. Evaluation of specimen adequacy is the most important aspect of quality assurance and for precise diagnosis in TBS. A systematic review and meta-analysis were carried out to assess the unsatisfactory specimen rate in the primary cervical cancer screening setting in Japan. Ovid Medline and Ichushi-Web databases were searched from inception through to May 2017. Prospective and retrospective studies that reported the proportion of unsatisfactory specimens in healthy asymptomatic Japanese women in a cervical cancer screening program were eligible for inclusion; 17 studies were included in the meta-analysis. The random-effects model meta-analysis calculated summary estimates of the unsatisfactory rate of 0.60% (95% confidence interval [CI], 0.18-1.96%; I2 = 99%) for conventional cytology and 0.04% (95% CI, 0.00-0.35%; I2 = 99%) for liquid-based cytology (LBC). However, comparative results between conventional and liquid-based cytology, based on four direct and nine comparative studies, showed no significant difference (summary odds ratio = 3.5 × 10-2 favoring LBC [95% CI, 6.9 × 10-4 -1.7]; I2 = 98%). In the subgroup analyses and meta-regressions, use of non-cotton devices for conventional cytology and use of a particular platform for LBC were associated with lower unsatisfactory rates. Meta-regression also suggested chronological improvement in unsatisfactory rates for both tests. In Japanese cervical cancer screening programs, conventional cytology remains prevalent. Future research needs to focus on evaluating the impact of screening programs using LBC by comparing the accuracy, performance, and cost-effectiveness with conventional cytology in the Japanese population.Entities:
Keywords: Bethesda system; cancer screening; cervical cancer; meta-analysis; unsatisfactory specimen rate
Mesh:
Year: 2018 PMID: 29478281 PMCID: PMC5891182 DOI: 10.1111/cas.13549
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716
Figure 1.Flow diagram of this systematic review of published reports and meta‐analysis of the frequency of unsatisfactory cervical cytology smears in Japanese women
Characteristics of studies reporting unsatisfactory specimens in healthy asymptomatic Japanese women (aged ≥20 years) who participated in a cervical cancer screening program
| Study ID (location)reference no. | Study years | No. of institutions | Sample size | Average age, years (range) | ≥ASCUS / ≥HSIL / cancer, |
|---|---|---|---|---|---|
| Direct comparison studies of LBC vs CC | |||||
| Ashikawa 2014 (Tokyo) | 2011 | Single center | 363 | 48 (26‐82) | 4.7/2.5/0 (CC); 4.9/2.6/0 (LBC) |
| Kuramoto 2015A (Kanagawa) | 2013‐2014 | Single center | 3483 | 50 (SD = 13) | 1.8/0.1/0.1 (CC); 1.6/0.1/0.0 (LBC) |
| Kuramoto 2015B (Kanagawa) | 2014 | Single center | 516 | 39 (SD = 23) | 2.3/0.4/0 (CC); 2.1/0.4/0 (LBC) |
| Furutate 2016 (Saitama) | 2014 (both); 2010‐2014 (CC) | Single center | 207 (both); 57 790 (CC) | ND | 5.3/1.0/0 (CC); 4.3/1.0/0 (LBC) |
| Indirect comparison studies of LBC vs CC | |||||
| Akamatsu 2005 (Niigata) | 2003 | Single center | 923 (CC); 17 049 (LBC) | ND | ND/0.1/0 (CC); ND/0.2/0 (LBC) |
| Akamatsu 2008 (Niigata) | 2005‐2006 | 3 centers | 26 644 (CC); 50 032 (LBC) | ND | ND/0.6/0.2 (CC) |
| Fujii 2012 (Tottori) | 2010 | 31 centers and mobile medical vehicles | 12 973 (CC); 8094 (LBC) | ND | 1.5/0.4/0.1 (total) |
| Kamei 2012 (Kanagawa) | 2010 (CC); 2010‐2011 (LBC) | Single center | 1835 (CC); 1796 (LBC) | ND | 1.8/0.4/0 (CC); 3.9/0.5/0 (LBC) |
| Tachibana 2013 (Chiba) | 2006‐2012 (CC); 2011‐2012 (LBC) | Single center | 609 297 (CC); 5934 (LBC) | 53 (20‐88) | ND/ND/ND (CC); 3.4/0.7/0.1 (LBC) |
| Kato 2016 (Ibaraki) | 2011‐2012 (CC); 2013‐2014 (LBC) | ND | 191 796 (CC); 191 741 (LBC) | ND | 2.1/ND/0.0 (CC); 2.5/ND/0.0 (LBC) |
| Kuroshima 2016 (Okinawa) | 2011‐2012 (CC); 2013‐2014 (LBC) | ND | 45 621 (CC); 45 129 (LBC) | 50 (17‐100) | 1.6/0.3/0.0 (CC); 3.3/0.6/0.0 (LBC) |
| Kuwakubo 2016 (Tochigi) | 2012 (CC); 2013 (LBC) | Multicenter | 12 063 (CC); 12 486 (LBC) | ND | 2.5/0.3/0.1 (CC); 3.1/0.4/0.1 (LBC) |
| Non‐comparative studies of CC | |||||
| Kuramoto 2009 (Kanagawa) | 2009 | Single center | 1967 | ND | 4.0/0/0 |
| Shirayama 2011 (Tokyo) | 2008 | 46 centers | 1273 | ND | ND |
| Takano 2011 (Chiba) | 2009‐2010 | 18 centers and mobile medical vehicles | 15 514 | ND | ND |
| Morimura 2012 (Fukushima) | 2008 | Multicenter | 69 584 | ND | ND |
| Morimura 2013 (Fukushima) | 2009‐2011 | 114 centers | 108 025 | 45‐49 (ND) | ND |
ASCUS, atypical squamous cells of undetermined significance; CC, conventional cytology; HSIL, high‐grade squamous intraepithelial lesion; LBC, liquid‐based cytology; ND, no data; SD, standard deviation.
Data pertaining to indirect comparison also reported.
Based on the whole study population, not from the subjects from whose date unsatisfactory rates were calculated.
Test characteristics and diagnostic criteria included in studies of cervical cancer screening programs in Japan
| Study IDreference no. | Sample collection device (CC) | Sample collection device (LBC) | LBC platform | Cytological classification system |
|---|---|---|---|---|
| Direct comparison studies of LBC vs CC | ||||
| Ashikawa 2014 | Cervex‐Brush | Cervex‐Brush | SurePath | “Bethesda 2001” |
| Kuramoto 2015A | Cervex‐Brush | Cervex‐Brush | TACAS Pro | “Bethesda 2001” |
| Kuramoto 2015B | Cytopick α | Cytopick α | TACAS Pro | “Bethesda 2001” |
| Furutate 2016 | Cervex‐Brush (ND for CC only) | Cervex‐Brush (ND for LBC only) | ThinPrep | “Bethesda 2001” |
| Indirect comparison studies of LBC vs CC | ||||
| Akamatsu 2005 | Cotton swab | Cotton swab or Cervex‐Brush | SurePath | Squamous cellularity, % of obscure field, and endocervical transformation zone component by Bethesda 2001 and Bethesda 1991 |
| Akamatsu 2008 | Cotton swab or spatula | Cervex‐Brush, cotton swab, spatula, or others | SurePath | Squamous cellularity, % of obscure field, and endocervical transformation zone component by Bethesda 2001 and Bethesda 1991 |
| Fujii 2012 | Cotton swab | Cervex‐Brush | SurePath | Squamous cellularity and % of obscure field by Bethesda 2001 |
| Kamei 2012 | Cotton swab | Cervex‐Brush | SurePath | Squamous cellularity by Bethesda 2001 |
| Tachibana 2013 | ND | Cervex‐Brush | SurePath | “Bethesda system” |
| Kato 2016 | Cotton swab, brush, spatula, or others | Cotton swab, brush, spatula, or others | SurePath | “Bethesda system” |
| Kuroshima 2016 | Mostly cotton swab | Cervex‐Brush, EndoCervex‐Brush, or Cervex‐Brush Combi | SurePath | “Bethesda 2001” |
| Kuwakubo 2016 | ND | ND | SurePath | “Bethesda 2001” |
| Non‐comparative studies of CC | ||||
| Kuramoto 2009 | Cotton swab and cytobrush | NA | NA | “Bethesda 2001” |
| Shirayama 2011 | Cotton swab, brush, or cytopick | NA | NA | Squamous cellularity and % of obscure field by Bethesda 2001 |
| Takano 2011 | ND | NA | NA | “Bethesda 2001” |
| Morimura 2012 | ND | NA | NA | Squamous cellularity by Bethesda 2001 |
| Morimura 2013 | Cotton swab, spatula, or brush | NA | NA | “Bethesda 2001” |
CC, conventional cytology; LBC, liquid‐based cytology; NA, not applicable; ND, no data.
Subgroup data based on squamous cellularity and percentage of obscure field by Bethesda 2001 only are also reported.
No observed atypical cells were also required. Collection devices: CervexBrush (Rovers Medical Devices, Oss, Netherlands); SurePath (Becton Dickinson, Franklin Lakes, NJ, USA); TACAS pro (Medical & Biological Laboratories, Nagoya, Japan); ThinPrep (Hologic Inc., Marlborough, MA, USA).
Figure 2Meta‐analysis of the unsatisfactory specimen rate using conventional cytology in the primary cervical cancer screening setting in Japan, according to sampling device. Diamonds depict the summary unsatisfactory specimen rate with the 95% confidence interval (CI). Each square and horizontal line indicates the unsatisfactory rate and the corresponding 95% CI, respectively, for each study. †Studies that jointly analyzed multiple different collection devices (no separate data reported). Collection devices: CervexBrush (Rovers Medical Devices, Oss, Netherlands); Cytopick (Matsunami Glass Ind., Ltd., Osaka, Japan)
Figure 3Meta‐analysis of the unsatisfactory specimen rate using liquid‐based cytology in the primary cervical cancer screening setting in Japan, according to cytology platform and sampling device. Diamonds depict the summary unsatisfactory rate with the 95% confidence interval (CI). Each square and horizontal line indicates the unsatisfactory rate and the corresponding 95% CI, respectively, for each study. Collection devices: CervexBrush (Rovers Medical Devices, Oss, Netherlands); SurePath (Becton Dickinson, Franklin Lakes, NJ, USA); TACAS Pro (Medical & Biological Laboratories, Nagoya, Japan); and ThinPrep (Hologic Inc., Marlborough, MA, USA). Misc, data based on joint analysis of multiple different collection devices
Figure 4Meta‐analysis of studies that compared unsatisfactory specimen rates between conventional cytology (CC) and liquid‐based cytology (LBC) in the primary cervical cancer screening setting in Japan. Diamonds depict the summary odds ratio with the 95% confidence interval (CI). Each square and horizontal line indicates the odds ratio and the corresponding 95% CI, respectively, for each study. Point estimates and their 95% CIs are based on the “empirical” continuity zero‐event correction